Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HPi1 是一种有口服活性的,针对幽门螺杆菌的选择性抗菌剂,IC50为 0.24 μM,MIC 为 0.08-0.16 μg/mL。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 185 | 现货 | ||
5 mg | ¥ 397 | 现货 | ||
10 mg | ¥ 663 | 现货 | ||
25 mg | ¥ 1,190 | 现货 | ||
50 mg | ¥ 1,990 | 现货 | ||
100 mg | ¥ 2,820 | 现货 | ||
200 mg | ¥ 3,970 | 现货 | ||
500 mg | ¥ 6,390 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 359 | 现货 |
产品描述 | HPi1 is a selective and orally active antimicrobial against Helicobacter pylori (IC50: 0.24 μM and a MIC of 0.08-0.16 μg/mL). HPi1 is inactive against other Xaliproden, including the gut commensals, Lactobacillus reuteri, Lactobacillus casei, and Bifidobacterium longum. |
靶点活性 | Antibacterial:(MIC)0.08-0.16 μg/ml(Helicobacter pylori), Antibacterial:0.24 μM |
体外活性 | HPi1 is effective against the clarithromycin-resistant strains ARHp172 (MIC of 0.004–0.016 μg/mL) and ARHp246 (MIC of 0.008–0.032 μg/mL). HPi1 has some activity against the Bacteroides species, but at concentrations at least 18-fold higher than the H. pylori MIC. HPi1 has good physicochemical and pharmacological properties, including determining the aqueous solubility (19 μg/mL), human plasma protein binding (93% bound), stability with human liver microsomes (T1/2 of 1.3 hours), and the ability to passively permeate membranes. The MIC against H. pylori isolates ranged from 0.002-0.032 μg/mL (0.01-0.17 μM) in the agar dilution assay. More potent activity is detected for Campylobacter jejuni with a MIC of 0.3 μg/mL. |
体内活性 | Treated with HPi1 (6.25-50 mg/kg; Oral gavage; once a day; for 3 days; female C57BL/6 mice), reduces colony counts below the limit of detection at doses of 25 or 50 mg/kg/day. |
分子量 | 192.24 |
分子式 | C8H8N4S |
CAS No. | 13080-21-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (312.11 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 5.2018 mL | 26.0092 mL | 52.0183 mL | 130.0458 mL |
5 mM | 1.0404 mL | 5.2018 mL | 10.4037 mL | 26.0092 mL | |
10 mM | 0.5202 mL | 2.6009 mL | 5.2018 mL | 13.0046 mL | |
20 mM | 0.2601 mL | 1.3005 mL | 2.6009 mL | 6.5023 mL | |
50 mM | 0.104 mL | 0.5202 mL | 1.0404 mL | 2.6009 mL | |
100 mM | 0.052 mL | 0.2601 mL | 0.5202 mL | 1.3005 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
HPi1 13080-21-2 Microbiology/Virology Others Antibacterial membranes Helicobacter ulcer Antimicrobial gastric inhibit Inhibitor Bacterial permeate HPi 1 HPi-1 orally pylori peptic inhibitor